drugset

drugset / Trial / NCT01973114

Latanoprost for the Treatment of Menière's Disease

NCT01973114 ↗

Phase 2 Unknown 100 enrolled Synphora AB

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the dose regimen, efficacy and safety of latanoprost for the treatment of Menière's disease.

Timeline

Start: 2013-10
Primary completion: 2016-05
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Latanoprost	Small molecule	—	Other

Indications